FITC-Linked Polyclonal Antibody to Fibrinogen Like Protein 1 (FGL1) Homo sapiens (Human) Labelled antibody

FGL-1; HFREP1; HP-041; LFIRE1; Hepassocin; Hepatocyte-derived fibrinogen-related protein 1; Liver fibrinogen-related protein 1

Add to Cart Distributors
Overview
Properties
  • SourceAntibody labeling
  • Ig Type IgG, Potency n/a
  • PurificationAntigen-specific affinity chromatography followed by Protein A affinity chromatography
  • LabelFITC
  • Original Antibody n/a
  • Buffer FormulationPBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
  • TraitsLiquid, Concentration 500µg/mL
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • FITC-Linked Polyclonal Antibody to Fibrinogen Like Protein 1 (FGL1) Packages (Simulation)
  • FITC-Linked Polyclonal Antibody to Fibrinogen Like Protein 1 (FGL1) Packages (Simulation)
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Specifity

The antibody is a rabbit polyclonal antibody raised against FGL1. It has been selected for its ability to recognize FGL1 in immunohistochemical staining and western blotting.

Usage

Western blotting: 0.2-2µg/mL;1:250-2500
Immunohistochemistry: 5-20µg/mL;1:25-100
Immunocytochemistry: 5-20µg/mL;1:25-100
Optimal working dilutions must be determined by end user.

Storage

Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Giveaways

Citations

  • The role of Hepassocin in the development of non-alcoholic fatty liver diseasePubmed: 23792031
  • Serum hepassocin concentrations in diabetic patients with or without nonalcoholic fatty liver diseaseFuturemedicine:Source
  • Compositions and Methods for Diagnosing Lung Cancery2016:0077095.html
  • Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCCDoi: 10.1016/j.cell.2018.09.053
  • Do different bariatric surgery procedures impact hepassocin plasma levels in patients with type 2 diabetes mellitus?
  • Impacts of Different Modes of Bariatric Surgery on Plasma Levels of Hepassocin in Patients with Diabetes Mellitus

Recommend products